Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Effect of Avelumab to Immune Response in AML: A Phase I Study of Avelumab in Combination with Decitabine As First Line Treatment of Unfit Patients

Hong Zheng, MD PhD, Shin Mineishi, David F. Claxton, MD, Junjia Zhu, Chenchen Zhao, MD, Bei Jia, MD PhD, W. Christopher Ehmann, MD, Seema Naik, MD, Natthapol Songdej, Raymond J. Hohl

Blood (2019) 134 (Supplement_1): 3939.

https://doi.org/10.1182/blood-2019-125153

Published: 2019

Journal Articles

Non-Myeloablative Allogeneic Stem Cell Transplant in Acute Myeloid Leukemia: Graft-Versus-Host Disease Potentiates Graft-Versus-Leukemia Effect and Improves Overall Survival

Christopher J Pizzola, MD MPH, Kevin L Rakszawski, MD, W. Christopher Ehmann, MD, Witold B. Rybka, MD, Baldeep Wirk, MD, Seema Naik, MD, Hong Zheng, MD PhD, Brook Silar, Gina Mackey, CCRP, Shin Mineishi, MD, Kentaro Minagawa, MD PhD, David F. Claxton, MD

Blood (2019) 134 (Supplement_1): 5724.

https://doi.org/10.1182/blood-2019-128817

Published: 2019

Journal Articles

TIGIT Expression Positively Associates with NK Cell Function in AML Patients

Bei Jia, MD PhD, Chenchen Zhao, MD, David F. Claxton, MD, W. Christopher Ehmann, MD, Witold B. Rybka, Shin Mineishi, Seema Naik, Natthapol Songdej, Muhammad Khawaja, Raymond J. Hohl, Hong Zheng, MD PhD

Blood (2018) 132 (Supplement 1): 5250.

https://doi.org/10.1182/blood-2018-99-113578

Published: 2018

Journal Articles

The Mantle Cell Lymphoma Response to VCR Protocol Associated with Its Sensitivity to Hypomethylation Regulation-a Collateral Study on VCR Phase I Trial

Jeffrey J Pu, MD PhD, Matthew Nemesure, W. Christopher Ehmann, MD, David F Claxton, MD, Joseph J Drabick, MD, Anna C Salzberg, Yuka I Kawasawa, PhD, Elliot Epner, MD PhD

Blood (2018) 132 (Supplement 1): 5295.

https://doi.org/10.1182/blood-2018-99-118192

Published: 2018

Journal Articles

Multi-Dimensional Analysis of Immune Signature Predicts Response to Decitabine Treatment in Elderly Patients with AML

Chenchen Zhao, MD, Bei Jia, MD PhD, Liru Wang, David F. Claxton, MD, W. Christopher Ehmann, MD, Witold B. Rybka, Shin Mineishi, Seema Naik, Natthapol Songdej, Muhammad Khawaja, Raymond J. Hohl, Hong Zheng, MD PhD

Blood (2018) 132 (Supplement 1): 1526.

https://doi.org/10.1182/blood-2018-99-113547

Published: 2018

Journal Articles

The Results of a Phase I Study using Velcade (Bortezomib), Cladribine, and Rituximab (VCR) in treating Mantle Cell Lymphoma

Jeffrey J. Pu, MD PhD, W. Christopher Ehmann, MD, Jason Liao, PhD, Christine Capper, BSN, Michelle Levy, MD, David F. Claxton, MD, Witold B. Rybka, MD, Raymond J. Hohl, MD PhD, Elliot M. Epner, MD PhD

Blood (2016) 128 (22): 1792.

https://doi.org/10.1182/blood.V128.22.1792.1792

Published: 2016

Journal Articles

Final Results of a Phase 1-2 Study of Vorinostat (SAHA), Cladribine, and Rituximab (SCR) Relapsed B-Cell Non-Hodgkin’s Lymphoma and Previously Untreated Mantle Cell Lymphoma

Stephen Spurgeon, MD, Kamal Sharma, DO, David F. Claxton, MD, Christopher Ehmann, MD, Sara Shimko, BS, August Stewart, Samir Parekh, MD, Violetta V. Leshchenko, PhD, Yiyi Chen, PhD, Motomi Mori, Jeffrey J. Pu, MD PhD, Elliot Epner, MD PhD

Blood (2014) 124 (21): 1714.

https://doi.org/10.1182/blood.V124.21.1714.1714

Published: 2014

Journal Articles

Utilization of Total Body Irradiation Is Not Necessary for Unrelated Donor Umbilical Cord Blood Transplants: a Single-Center Experience

Jeffrey J. Pu, MD PhD, Elizabeth L Miller, Arthur Berg, PhD, Melanie Comito, Robert J. Greiner, MD, W. Christopher Ehmann, MD, David F. Claxton, MD, Witold B Rybika

Blood (2014) 124 (21): 5844.

https://doi.org/10.1182/blood.V124.21.5844.5844

Published: 2014

Journal Articles

Early Discharge and Out Patient Management After AML Induction Chemotherapy: Determinants of Safety

Roberto A Ferro, MD, Junjia Zhu, Ph.D, W. Christopher Ehmann, MD, Susan Rokita, CRNP, MSN, Vicki Haight, CRNP, MSN, Jo Ann Davidson, CRNP, MSN, Constance Berk, PA-C, Witold Rybka, MD, David F. Claxton, MD

Blood (2012) 120 (21): 2054.

https://doi.org/10.1182/blood.V120.21.2054.2054

Published: 2012

Journal Articles

Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin + Rituximab Followed by Stem Cell Transplantation in Relapsed/Refractory DLBCL Patients: Safety and Efficacy

Nina Wagner-Johnston, MD, Andre Goy, MD, Maria Alma Rodriguez, MD, Christopher Ehmann, MD, Paul Hamlin, MD, John Radford, MD, Catherine Thieblemont, MD, Cheolwon Suh, MD, John Sweetenham, MD, Ying Jiang, PhD, Sharon T Sullivan, PhD, Erik R Vandendries, MD, PhD, Christian Gisselbrecht, MD

Blood (2011) 118 (21): 2718.

https://doi.org/10.1182/blood.V118.21.2718.2718

Published: 2011

Journal Articles

Inotuzumab Ozogamicin (CMC-544) In Patients with Indolent B-Cell NHL That Is Refractory to Rituximab Alone, Rituximab and Chemotherapy, or Radioimmunotherapy: Preliminary Safety and Efficacy From a Phase 2 Trial

Andre Goy, MD, Joseph Leach, MD, W. Christopher Ehmann, MD, Kiyoshi Ando, MD, PhD, Kiyohiko Hatake, MD, PhD, Kensei Tobinai, MD, PhD, Tatyana Feldman, MD, Steven Hua, Angela DG Volkert, Erik R. Vandendries, MD, PhD, Michinori Ogura, MD, PhD

Blood (2010) 116 (21): 430.

https://doi.org/10.1182/blood.V116.21.430.430

Published: 2010

Journal Articles

Clofarabine, Etoposide and Mitoxantrone In the Therapy of Relapsed and Refractory Acute Myelogenous Leukemia

W. Christopher Ehmann, MD, Sulfikar Ibrahim, MD, Witold Rybka, MD, David F. Claxton, MD

Blood (2010) 116 (21): 4353.

https://doi.org/10.1182/blood.V116.21.4353.4353

Published: 2010

Journal Articles

Fludarabine-Associated Acute Promyelocytic Leukemia

Clayton B Hess, BA, W. Christopher Ehmann, MD

Blood (2010) 116 (21): 4383.

https://doi.org/10.1182/blood.V116.21.4383.4383

Published: 2010

Journal Articles

Sirolimus for Graft-Versus-Host-Diseases Prophylaxis in Non-Myeloablative Matched Related Transplantation: Safety and Efficacy.

Hong Zheng, MD, PhD, Michelle Carraher, BA, Eric Schaefer, M.A., Giampaolo Talamo, MD, W. Christopher Ehmann, MD, Witold Rybka, David F. Claxton, M.D.

Blood (2009) 114 (22): 4329.

https://doi.org/10.1182/blood.V114.22.4329.4329

Published: 2009

Journal Articles

Non-Myeloablative Hematopoietic Transplant with Sirolimus Immunosuppression: Determinants of Outcome.

David F. Claxton, MD, Chuancai Wang, PhD, Michelle Carraher, Christopher Ehmann, MD, Witold Rybka, MD

Blood (2005) 106 (11): 5462.

https://doi.org/10.1182/blood.V106.11.5462.5462

Published: 2005

Journal Articles

Identification of a Second Acute Promyelocytic Leukemia (APL) Patient with the STAT5b-RARα Fusion Gene among PML-RARα-Negative Eastern Cooperative Oncology Group (ECOG) APL Protocol Registrants.

Robert E. Gallagher, MD, Serena Mak, BA, Elisabeth Paietta, PhD, Brenda Cooper, MD, W. Christopher Ehmann, MD, Martin S. Tallman, MD

Blood (2004) 104 (11): 3005.

https://doi.org/10.1182/blood.V104.11.3005.3005

Published: 2004

NARROW

Effect of Avelumab to Immune Response in AML: A Phase I Study of Avelumab in Combination with Decitabine As First Line Treatment of Unfit Patients

Non-Myeloablative Allogeneic Stem Cell Transplant in Acute Myeloid Leukemia: Graft-Versus-Host Disease Potentiates Graft-Versus-Leukemia Effect and Improves Overall Survival

TIGIT Expression Positively Associates with NK Cell Function in AML Patients

The Mantle Cell Lymphoma Response to VCR Protocol Associated with Its Sensitivity to Hypomethylation Regulation-a Collateral Study on VCR Phase I Trial

Multi-Dimensional Analysis of Immune Signature Predicts Response to Decitabine Treatment in Elderly Patients with AML

The Results of a Phase I Study using Velcade (Bortezomib), Cladribine, and Rituximab (VCR) in treating Mantle Cell Lymphoma

Final Results of a Phase 1-2 Study of Vorinostat (SAHA), Cladribine, and Rituximab (SCR) Relapsed B-Cell Non-Hodgkin’s Lymphoma and Previously Untreated Mantle Cell Lymphoma

Utilization of Total Body Irradiation Is Not Necessary for Unrelated Donor Umbilical Cord Blood Transplants: a Single-Center Experience

Early Discharge and Out Patient Management After AML Induction Chemotherapy: Determinants of Safety

Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin + Rituximab Followed by Stem Cell Transplantation in Relapsed/Refractory DLBCL Patients: Safety and Efficacy

Inotuzumab Ozogamicin (CMC-544) In Patients with Indolent B-Cell NHL That Is Refractory to Rituximab Alone, Rituximab and Chemotherapy, or Radioimmunotherapy: Preliminary Safety and Efficacy From a Phase 2 Trial

Clofarabine, Etoposide and Mitoxantrone In the Therapy of Relapsed and Refractory Acute Myelogenous Leukemia

Fludarabine-Associated Acute Promyelocytic Leukemia

Sirolimus for Graft-Versus-Host-Diseases Prophylaxis in Non-Myeloablative Matched Related Transplantation: Safety and Efficacy.

Non-Myeloablative Hematopoietic Transplant with Sirolimus Immunosuppression: Determinants of Outcome.

Identification of a Second Acute Promyelocytic Leukemia (APL) Patient with the STAT5b-RARα Fusion Gene among PML-RARα-Negative Eastern Cooperative Oncology Group (ECOG) APL Protocol Registrants.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only